08/09/2026
For years we called it PCOS: polycystic o***y syndrome. This year, that name officially began its shift to PMOS: polyendocrine metabolic ovarian syndrome, following a global consensus published in The Lancet, shaped by input from more than 14,000 patients and health professionals. It's not a new condition - it's a more honest name for the one we've always been treating. The "cysts" on ultrasound were never true cysts anyway; they're immature follicles, and this was never just an ovarian condition.
Which brings me to why the rename matters clinically, not just semantically.
Medicine organises PMOS into four phenotypes based on what's present - ⬆️ androgens, ⬇️ovulation, ovarian morphology, in different combinations. Useful for diagnosis. But it doesn't tell us why those features are showing up in your particular client.
The naturopathic lens - where I live as a practitioner - asks a different question: what's actually driving the high androgens and the PMOS presentation?
1️⃣ Insulin resistance - the most common driver, but not always the one at play
2️⃣ Inflammation
3️⃣ Post-pill rebound
4️⃣ Adrenal androgen excess
Same syndrome, same phenotype even - but a completely different treatment plan depending on which driver you're looking at. That's the piece the medical model still misses: its therapeutic approach has largely stayed uniform, applied to everyone regardless of which subtype they actually have.
The new name gets the label right. Finding the driver is arguably what actually changes the outcome.